Long-term safety of facilitated subcutaneous immunoglobulin: Insights from a postauthorization safety study in primary immunodeficiency diseases (PID)

被引：0
|
作者：
Rubinstein, Arye [1 ,2 ]
Patel, Niraj C. [3 ]
Wedner, H. James [4 ]
Wasserman, Richard L. [5 ]
Gupta, Sudhir [6 ]
Fielhauer, Katharina [7 ]
Chavan, Shailesh [8 ]
Yel, Leman [9 ]
机构：
[1] Albert Einstein Coll Med, Bronx, NY 10467 USA
[2] Montefiore Hosp, Bronx, NY USA
[3] Atrium Hlth, Levine Childrens Hosp, Charlotte, NC USA
[4] Washington Univ, Barnes Jewish Hosp, Sch Med, St Louis, MO USA
[5] Allergy Partners North Texas Res, Dallas, TX USA
[6] Univ Calif Irvine, Irvine, CA USA
[7] Baxalta Innovat GmbH, Vienna, Austria
[8] Shire US Inc, Lexington, MA USA
[9] Baxalta US Inc, Cambridge, MA USA
来源：
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM | 2021年 / 26卷 / 03期
关键词：
facilitated subcutaneous immunoglobulin; real-world data; safety study; chronic inflammatory demyelinating polyradiculoneuropathy;
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
65
引用
收藏
页码：334 / 335
页数：2
相关论文
共 50 条
  • [41] Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases
    Wasserman, Richard L.
    IMMUNOTHERAPY, 2017, 9 (12) : 1035 - 1050
  • [42] Facilitated subcutaneous immunoglobulin: A long-term follow-up in a cohort of patients with common variable immunodeficiency
    Pedini, V
    Menghini, D.
    Gelardi, C.
    Danieli, G.
    Danieli, M. G.
    Gabrielli, A.
    ALLERGY, 2018, 73 : 305 - 305
  • [43] Efficacy, Safety and Pharmacokinetics of a Novel Subcutaneous Immunoglobulin, Evogam®, in Primary Immunodeficiency
    Marianne B. Empson
    Mimi L. K. Tang
    Lisa K. C. Pearce
    Leon Rozen
    Michael S. Gold
    Constance H. Katelaris
    David Langton
    Joanne Smart
    William B. Smith
    Richard H. Steele
    John B. Ziegler
    Darryl Maher
    Journal of Clinical Immunology, 2012, 32 : 897 - 906
  • [44] Efficacy, Safety and Pharmacokinetics of a Novel Subcutaneous Immunoglobulin, Evogam®, in Primary Immunodeficiency
    Empson, Marianne B.
    Tang, Mimi L. K.
    Pearce, Lisa K. C.
    Rozen, Leon
    Gold, Michael S.
    Katelaris, Constance H.
    Langton, David
    Smart, Joanne
    Smith, William B.
    Steele, Richard H.
    Ziegler, John B.
    Maher, Darryl
    JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 (05) : 897 - 906
  • [45] Long-term efficacy, safety, and tolerability of recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin (Ig) (fSCIG; HyQvia(R)) in immunodeficiency diseases: real-life data from a monocentric experience
    Angelotti, Francesca
    Capecchi, Riccardo
    Giannini, Daiana
    Mazzarella, Ornella
    Rocchi, Valeria
    Migliorini, Paola
    CLINICAL AND EXPERIMENTAL MEDICINE, 2020, 20 (03) : 387 - 392
  • [46] Real-World Use, Safety, and Patient Experience of 20% Subcutaneous Immunoglobulin for Primary Immunodeficiency Diseases
    Fasshauer, Maria
    Borte, Michael
    Bitzenhofer, Michaela
    Pausch, Christine
    Pittrow, David
    Park, Michelle
    Gladiator, Andre
    Jandus, Peter
    ADVANCES IN THERAPY, 2023, 40 (12) : 5168 - 5187
  • [47] Erratum to: Efficacy and Safety of IgPro20, a Subcutaneous Immunoglobulin, in Japanese Patients with Primary Immunodeficiency Diseases
    Hirokazu Kanegane
    Kohsuke Imai
    Masafumi Yamada
    Hidetoshi Takada
    Tadashi Ariga
    Martin Bexon
    Mikhail Rojavin
    Wilson Hu
    Midori Kobayashi
    John-Philip Lawo
    Shigeaki Nonoyama
    Toshiro Hara
    Toshio Miyawaki
    Journal of Clinical Immunology, 2014, 34 : 520 - 520
  • [48] Safety and Efficacy of Home-Based Subcutaneous Immunoglobulin G in Elderly Patients with Primary Immunodeficiency Diseases
    Stein, Mark R.
    Koterba, Alan
    Rodden, Linda
    Berger, Melvin
    POSTGRADUATE MEDICINE, 2011, 123 (05) : 186 - 193
  • [49] Real-World Use, Safety, and Patient Experience of 20% Subcutaneous Immunoglobulin for Primary Immunodeficiency Diseases
    Maria Fasshauer
    Michael Borte
    Michaela Bitzenhofer
    Christine Pausch
    David Pittrow
    Michelle Park
    André Gladiator
    Peter Jandus
    Advances in Therapy, 2023, 40 : 5168 - 5187
  • [50] Insights into Facilitated Subcutaneous Immunoglobulin Use in Patients with Secondary Immunodeficiency Diseases: A FIGARO Subgroup Analysis
    Dimou, Maria
    Speletas, Matthaios
    Milito, Cinzia
    Pyzik, Aleksandra
    Huscher, Doerte
    Kamieniak, Marta
    Pittrow, David
    Borte, Michael
    CANCERS, 2023, 15 (18)
12345